Q-omics provides the consensus-scored CEACAM18 profile across patient tissues and cancer cell-line models. CEACAM18 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CEACAM18 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, CEACAM18 RNA expression shows 8,026 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KICH, HNSC, and ESCA as cancer lineages where CEACAM18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEACAM18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEACAM18 survival associations across molecular data types. CEACAM18 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEACAM18 RNA expression–survival associations across cancer types. High CEACAM18 expression shows unfavorable associations in KICH, TGCT, THCA, LUSC, ESCA and MESO. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for CEACAM18 RNA expression.
This table summarizes CEACAM18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CEACAM18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEACAM18 shows lower tumor expression in PRAD and higher tumor expression in HNSC, PAAD, KIRC and COAD. The HNSC box plot shows higher CEACAM18 RNA expression in tumor versus normal tissue (log2 FC = +0.016, t-test p = .021).
This table shows molecular features associated with CEACAM18 in patient tissues and cancer cell lines. In patient samples, CEACAM18 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CEACAM18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
